NCT02034123 Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma Status TERMINATED Phase PHASE1
NCT02034097 A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer Status WITHDRAWN Phase PHASE2
NCT02033668 Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT02028676 Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa Status COMPLETED Phase PHASE4
NCT02027454 Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction Status COMPLETED Phase PHASE1
NCT02020889 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Status COMPLETED Phase PHASE3
NCT02019732 Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States Status COMPLETED Phase N/A
NCT02019719 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Status COMPLETED Phase PHASE2
NCT02019472 A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis Status COMPLETED Phase PHASE3
NCT02016963 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection Status COMPLETED Phase PHASE2/PHASE3
NCT02014662 A Methodology Study to Assess Muscle Damage After Eccentric Exercise Status COMPLETED Phase PHASE1
NCT02014584 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Status COMPLETED Phase PHASE3
NCT02014571 Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C. Status COMPLETED Phase PHASE1
NCT02014519 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary Status COMPLETED Phase NA
NCT02014480 A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Status COMPLETED Phase PHASE3
NCT02010645 Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) Status TERMINATED Phase PHASE2